Giostar India

What Giostar India does

Giostar India operates a network of stem cell hospitals and research centers in Ahmedabad and Bengaluru, providing regenerative therapies for degenerative, immunological, and genetic diseases. The company is the Indian subsidiary of GIOSTAR USA, headquartered in San Diego, California, and was founded under the leadership of Dr. Anand Srivastava. Its core offering is autologous and allogeneic stem cell therapy using adult stem cells, embryonic stem (ES) cells, and induced pluripotent stem (IPS) cells, with proprietary methods for stem cell isolation, mesenchymal stem cell (MSC) therapy, and differentiation into neural, blood, skin, and hair cell lineages. Treatment is administered locally or intravenously, targeting conditions including diabetes, cancer, liver disease, neurological disorders such as Alzheimer's and Parkinson's, arthritis, spinal cord injuries, COPD, and multiple sclerosis.

The business operates on a direct-to-consumer model, with patients booking appointments online or by phone and receiving pre-treatment counseling to confirm eligibility. Revenue is generated through professional services fees from clinical stem cell therapy procedures and ancillary offerings such as the Fountain of Youth IV vitamin therapy for anti-aging and wellness. The Ahmedabad facility, described as one of the largest stem cell hospitals globally and government-funded by Gujarat, was inaugurated by Narendra Modi during his tenure as Chief Minister. The company's distribution is centered on its two Indian hospital locations, supplemented by digital marketing across YouTube, Instagram, and Facebook, and it claims an international network of 10 branches spanning Asia, Middle East, Africa, North and South America, and Europe.

Giostar India is privately held with no disclosed funding rounds, revenue figures, or headcount data. Pricing is quote-based and determined after patient consultation. The company cites peer-reviewed publications in journals including J Stem Cell Res Ther, Case Reports in Dermatological Medicine, and FASEB J as evidence of research activity. Its growth strategy centers on domestic multi-city expansion in India and the development of new international Institutes of Regenerative Medicine, though no firm timelines, capital commitments, or operational metrics are publicly disclosed.

Name

Giostar India

Legal name

GIOSTAR India

Website

https://www.giostarindia.com

Company type

Private

Operating status

Operating

Short description

Giostar India operates stem cell hospitals and research centers in Ahmedabad and Bengaluru, delivering regenerative therapies for degenerative and genetic diseases. The Indian subsidiary of GIOSTAR USA serves individual patients directly through clinical stem cell treatments and ancillary wellness services.

Ownership category

akta.pro rank

Product category

Regenerative Medicine and Stem Cell Therapy Services

NAICS

Health Care and Social Assistance (62), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Health Services (8000), Services-Specialty Outpatient Facilities, Nec (8093)

akta.pro primary industry

Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)

akta.pro secondary industries

Stem Cell–Based Regenerative Therapies (HLAAAGAA), Cell Therapy Clinical Services & Treatment Centers (apheresis, administration, monitoring) (HLAAABAJ)

Keywords

• Stem cell therapy
• Regenerative medicine
• Cellular therapy hospitals
• Chronic disease treatment
• Degenerative disease therapy

Headquarters

HQ city

Ahmedabad

HQ country

India

HQ region

Asia

Offices2 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Clinical Stem Cell Therapy Services: Direct patient treatment services at hospital facilities offering stem cell therapies for various degenerative and genetic diseases including diabetes, cancer, liver diseases, neurological conditions, and more. Revenue generated through medical consultation, treatment procedures, and related healthcare services.
2. Anti-Aging IV Therapy: IV therapy services offering vitamin and mineral infusions (Fountain of Youth IV therapy) for aesthetic and wellness purposes, including B-5, B-Complex, Vitamin C, and Glutathione treatments.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Giostar India operates hospitals and research centers in Ahmedabad and Bengaluru that administer clinical stem cell therapies to patients suffering from degenerative, immunological, and genetic diseases such as diabetes, cancer, liver disease, Alzheimer's, Parkinson's, arthritis, spinal cord injuries, COPD, and other chronic conditions. The company uses adult stem cells, embryonic stem cells, and induced pluripotent stem cells, with treatments delivered via local or intravenous administration. Supporting services include pre-treatment medical counseling and aesthetic IV vitamin therapy.

Product overview

Giostar India operates as a network of stem cell hospitals and research centers offering regenerative medicine treatments. The core offering is Stem Cell Therapy for treating various degenerative, immunological, and genetic diseases. Supporting services include Medical Counseling to assess patient eligibility, and the Fountain of Youth IV Therapy for aesthetic purposes. The company has facilities in Ahmedabad and Bengaluru, India.

Differentiator

Problem solved

Functional benefit

Products and services

• Stem Cell Therapy

Quantifiable outcome

• 20000+ patients treated
• +1 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

Regional players

• Stempeucel (Stempeutics Research): India-based stem cell company developing allogeneic MSC therapies for indications including osteoarthritis, critical limb ischemia, and liver cirrhosis. Directly comparable as an Indian stem cell therapy developer with similar therapeutic ambitions, though Stempeutics focuses more on drug development versus GIOSTAR's clinic-services model.
• Medipost (Cartistem): Korean biotech with the first approved allogeneic umbilical cord blood-derived MSC product (Cartistem) for cartilage regeneration. Comparable as a commercial stem cell therapy provider in Asia operating in regenerative medicine, though focused on a narrower indication set.
• TotipotentRX (TRX) Cell Therapy: India-focused stem cell therapy provider offering regenerative treatments for orthopedic, neurological, and lifestyle diseases through clinic partnerships. Comparable as a direct competitor in the Indian stem cell clinic market with similar patient-facing delivery model.

Emerging players

• Mesoblast: Australia-listed cell therapy company developing MSC-based treatments for inflammatory conditions, heart failure, and chronic low back pain. Comparable as a commercial-stage MSC therapy developer with similar underlying stem cell biology, though focused on pharmaceutical-style product development versus GIOSTAR's clinic delivery.
• Athersys: US-based clinical-stage biotech developing MultiStem cell therapy for stroke, ARDS, and inflammatory conditions. Comparable as a stem cell therapeutics developer targeting similar regenerative indications (neurological, inflammatory), but pursuing regulatory approval pathways rather than direct clinic delivery.
• BrainStorm Cell Therapeutics: US/Israel-based developer of NurOwn, an autologous MSC-based therapy for ALS and other neurodegenerative diseases. Directly comparable in targeting neurological degenerative diseases (a core GIOSTAR indication) using stem cell biology, though operating as a biotech drug developer.
• Pluristem Therapeutics: Israeli cell therapy company using placenta-derived MSC-like cells for inflammatory, ischemic, and hematological conditions. Comparable as a stem cell therapeutics developer with similar MSC-based technology approach and overlapping indication interests.

Direct peers

• Regrow Biosciences: Mumbai-based stem cell and regenerative medicine company offering cell therapy services and developing products for orthopedic and wound healing indications. Directly competes with GIOSTAR in the Indian stem cell therapy market with similar business model of providing regenerative treatments to patients.
• Celltex Therapeutics: Houston-based adult stem cell banking and therapy company offering autologous MSC treatments for orthopedic, neurological, and autoimmune conditions at clinical scale. Comparable as a direct-to-consumer stem cell clinic operator with similar business model and indication breadth as GIOSTAR India.

Broad incumbents

• Smith+Nephew (via Osiris acquisition): Global medical devices company that acquired Osiris Therapeutics and markets cartilage regeneration products (e.g., Carticel, BioCartilage). Comparable as a major player in regenerative medicine with approved orthopedic stem cell products, representing the incumbent scale player GIOSTAR competes against in adjacent niches.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/@GioStar-USA-Ahmedabad
• Facebookfacebook.com/giostarhospitals
• Instagraminstagram.com/giostar_hospital_ahmedabad

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Giostar India